clinical trial · NCT06842823
A Study of Navenibart in Participants With Hereditary Angioedema
Astria Therapeutics, Inc.·phase3·active not recruiting·n = 157
Hereditary Angioedema (HAE)navenibartPlacebo
brief summary
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
started
Mar 20, 2025
primary completion
Dec 1, 2026
completion
Jun 1, 2027
last updated
Jun 30, 2026
official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants With Hereditary Angioedema (HAE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol